307 related articles for article (PubMed ID: 10676828)
1. Tamsulosin for the treatment of benign prostatic hypertrophy.
Lee M
Ann Pharmacother; 2000 Feb; 34(2):188-99. PubMed ID: 10676828
[TBL] [Abstract][Full Text] [Related]
2. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Chapple CR; Wyndaele JJ; Nordling J; Boeminghaus F; Ypma AF; Abrams P
Eur Urol; 1996; 29(2):155-67. PubMed ID: 8647141
[TBL] [Abstract][Full Text] [Related]
3. Tamsulosin for benign prostatic hyperplasia.
Wilt TJ; Mac Donald R; Rutks I
Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect.
Lowe FC
Clin Ther; 1997; 19(4):730-42. PubMed ID: 9377617
[TBL] [Abstract][Full Text] [Related]
5. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.
Dunn CJ; Matheson A; Faulds DM
Drugs Aging; 2002; 19(2):135-61. PubMed ID: 11950378
[TBL] [Abstract][Full Text] [Related]
6. Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
Lyseng-Williamson KA; Jarvis B; Wagstaff AJ
Drugs; 2002; 62(1):135-67. PubMed ID: 11790159
[TBL] [Abstract][Full Text] [Related]
7. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
8. WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.
Wilt TJ; Macdonald R; Rutks I
Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD002081. PubMed ID: 21901681
[TBL] [Abstract][Full Text] [Related]
9. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
10. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
Narayan P; Lepor H
Urology; 2001 Mar; 57(3):466-70. PubMed ID: 11248621
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia.
Milicevic S; Bijelic R
Med Arch; 2012; 66(3):173-6. PubMed ID: 22822617
[TBL] [Abstract][Full Text] [Related]
12. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia.
Wilde MI; McTavish D
Drugs; 1996 Dec; 52(6):883-98. PubMed ID: 8957159
[TBL] [Abstract][Full Text] [Related]
13. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
Eur Urol; 1996; 29(2):145-54. PubMed ID: 8647140
[TBL] [Abstract][Full Text] [Related]
14. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
Kawabe K; Yoshida M; Homma Y;
BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
17. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.
Abrams P; Schulman CC; Vaage S
Br J Urol; 1995 Sep; 76(3):325-36. PubMed ID: 7551841
[TBL] [Abstract][Full Text] [Related]
18. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
Cervenakov I; Fillo J
Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
20. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
Beduschi MC; Beduschi R; Oesterling JE
Urology; 1998 Jun; 51(6):861-72. PubMed ID: 9609620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
